Immunological
Insmed’s brensocatib has comprehensively failed in a mid-stage study in chronic rhinosinusitis, which would have been a second potential blockbuster indication for the DPP1 inhibitor.
After a developmental rollercoaster ride, the French firm is getting ready to refile Viaskin Peanut for 4-7 -year-olds in the first half of 2026.
The France-based biotech is making solid progress amid mounting talk of a sale.
After buying the rights to Dren Bio’s lead candidate, DR-0201, in March, Sanofi has again tapped the start-up for a new drug discovery and development agreement for a potential new autoimmune therapy.
Clinical Data Readout: As a worldwide first mover, InnoCare’s BTK inhibitor orelabrutinib has hit its monotherapy primary endpoint of SRI-4 response rate at 48 weeks in a China-only Phase IIb trial in systemic lupus erythematosus.
The rare disease blockbuster has stumbled in a key Phase III study, although Argenx still has plenty of other pipeline opportunities.
Through its buyout of San Diego-based startup Arthrosi, Sobi gains the URAT1 inhibitor pozdeutinurad (AR882) for gout, which is an existing area of focus for the Swedish firm.
Having worked in stealth on its predictive computational R&D models, PsiThera has emerged to develop oral versions of blockbuster drug targets in inflammation and immunology.
The deal, which could be worth as much as $1.7bn, looks to use Relation's AI capabilities to power the discovery of potentially first-in-class immuno-dermatology targets.
Novartis presented Phase III results for anti-BAFF/ADCC antibody ianalumab in the second-line treatment of immune thrombocytopenia but will wait for first-line data to file for approvals in 2027.
Early atopic dermatitis data on the oral STAT6 degrader helps the US firm’s hopes of matching the Sanofi and Regeneron injectable blockbuster on efficacy.
Roughly four months after raising its 2025 revenue forecast, UCB has done it again, helped by strong performance of its IL-17A and IL-17F inhibitor.
The Paris-headquartered giant has put the spotlight on its extensive investments at home.
Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.
The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.
Deal Snapshot: The biotech is joining forces with the Versant Ventures-backed startup, paying $50m upfront to apply its macrocycle peptide platform to immunological diseases.
Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.
The biopharma plans to advance the PD-1 agonist in rheumatoid arthritis despite its failure in ulcerative colitis.
In a world-first, Beijing Mabworks has scored a Phase III clinical win for its novel anti-CD20 antibody in the treatment of primary membranous nephropathy. However, multiple global contenders including Roche are threatening to come from behind in the race.
A late-stage win in the ALLEGORY study in SLE supports Roche’s push to expand Gazyva beyond oncology and into autoimmune diseases.